Entropy Technologies LP Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY

Entropy Technologies LP increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,461.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,181 shares of the biopharmaceutical company’s stock after acquiring an additional 16,081 shares during the quarter. Alnylam Pharmaceuticals makes up about 0.6% of Entropy Technologies LP’s portfolio, making the stock its 29th biggest holding. Entropy Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $7,835,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ALNY. Kennedy Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 93.0% during the third quarter. Kennedy Capital Management LLC now owns 3,220 shares of the biopharmaceutical company’s stock worth $1,468,000 after purchasing an additional 1,552 shares during the period. Certuity LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $213,000. Quadrature Capital Ltd increased its holdings in shares of Alnylam Pharmaceuticals by 2,492.5% during the 3rd quarter. Quadrature Capital Ltd now owns 48,920 shares of the biopharmaceutical company’s stock worth $22,299,000 after buying an additional 47,033 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the period. Finally, Employees Retirement System of Texas raised its position in shares of Alnylam Pharmaceuticals by 3.4% during the 3rd quarter. Employees Retirement System of Texas now owns 9,792 shares of the biopharmaceutical company’s stock valued at $4,465,000 after buying an additional 318 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares in the company, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Down 1.0%

ALNY opened at $317.23 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The business has a fifty day simple moving average of $346.09 and a 200-day simple moving average of $410.94. The firm has a market cap of $42.07 billion, a P/E ratio of 185.51 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the prior year, the firm posted ($0.65) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ALNY shares. Wells Fargo & Company lowered their price objective on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Leerink Partners cut their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Finally, Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.